You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Mitochondrial DNA repair agents for acute lung injury

    SBC: EXSCIEN CORPORATION            Topic: NHLBI

    DESCRIPTION provided by applicant Attempts to develop drug treatments for acute lung injury ALI and the acute respiratory distress syndrome ARDS have been marred by unfulfilled expectations Such failures often attributed to the heterogeneous pathophysiology of ALI ARDS and uncertainty about molecular targets of drug action have combined to fuel considerable skepticism about future dru ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Humanized Monoclonal Antibody to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTIONprovided by applicantThe world needs a highly effective malaria vaccineSanaria rPfSPZ Vaccinecomposed of asepticpurifiedcryopreserved radiation attenuated PfSPZprotectedof volunteers in an NIH clinical trialThe vaccine has been administered by direct venous inoculationDVItosubjects in MaliTanzaniaEquatorial GuineaEGand USASafetytolerabilityhigh grade protectionheterologous protection af ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Arenavirus Antiviral Lead Optimization

    SBC: Arisan Therapeutics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Arenaviruses comprise a diverse family Several species are associated with severe arenaviral hemorrhagic fever AVHF in humans that exhibit case fatality rates as high as Human infection with arenaviruses typically occurs through contact with materials contaminated with the excretions of an infected rodent although direct human to human transmission may ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Arrayed drug microinjection for guiding precision medicine in relapsed lymphoma

    SBC: PRESAGE BIOSCIENCES, INC.            Topic: 102

    DESCRIPTIONprovided by applicantImprovements in cancer diagnostics and therapeutics have positively impacted outcomes for oncology patients within select clinical nichesHoweversignificant therapeutic uncertainty awaits the majority of today s oncology patients who present in the clinic with cancer that will relapse after exhibiting an initial response or whose cancer is already refractory to stand ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced morphological analysis of cerebral blood flow for acute concussion diagnosis and return to play determination

    SBC: Neural Analytics, Inc.            Topic: 101

    Project Summary Abstract Between and million people each year suffer a mild TBI in the US alone Reliable diagnosis and prompt treatments are vital to managing the often serious short and long term sequelae resulting from mild TBI However a reliable objective and accurate method for mild TBI diagnosis outside of a hospital setting and in particular for determining RTP readiness has e ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. An immune based approach for HIV eradication

    SBC: RETROVIROX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Viral reservoir eradication has become a leading subject in the field of HIV research A plethora of antiretrovirals ARVs are available to efficiently treat infection Living with HIV has become a chronic disease in which viral load can be controlled in over ninety percent of patients Yet the health social and economical burden of the disease are unpre ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. In Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTION provided by applicant Sanariaandapos s platform technology is production of aseptic purified cryopreserved Plasmodium falciparum Pf sporozoites SPZ This technology has produced three products administered by needle and syringe all of which are in clinical trials PfSPZ Vaccine radiation attenuated PfSPZ PfSPZ Challenge infectious PfSPZ for controlled human malaria infec ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Genetically Attenuated PfSPZ Malaria Vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTION provided by applicant We build on the successful work in Phase II SBIR R AI in which a genetically attenuated Plasmodium falciparum Pf parasite GAP was produced and shown to generate aseptic Pf sporozoites SPZ that invade hepatocytes but do not replicate We will use this genetically attenuated double mutant parasite deficient in the genes encoding SLARP and B Pf ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical and Non Clinical Evaluations of repeat administrations of the FAST PV and mGFR Technology

    SBC: PHARMACOPHOTONICS, INC.            Topic: 400

    DESCRIPTION provided by applicant Pharmaco Photonics DBA FAST Biomedical proposes a PHASE IIB project to determine the safety and functionality of repeat administration of the FAST PV and mGFR Technology in both non clinical and clinical studies The long term goal of this SBIR project is to test FASTandapos s fluorescent based test in humans and commercializes this product for rapid detecti ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government